PURPOSE: SJG-136 is a pyrrolobenzodiazepine dimer that forms DNA crosslinks and has demonstrated broad antitumor activity. We undertook this trial to determine the maximum-tolerated dose (MTD), toxicities and pharmacokinetic (PK) profile of SJG-136 in patients with an advanced solid tumor. PATIENTS AND METHODS: In this phase I study, patients were treated with SJG-136 on days 1, 8 and 15 of a 28-day cycle. Dose levels studied were 10, 20, 40 and 60 microg/m2. PK parameters of SJG-136 were assessed following the intravenous administration of SJG-136 on days 1 and 15 of cycle 1. RESULTS: Twenty-one patients with advanced solid tumors were treated. Patients had a median of two prior chemotherapy regimens. Fatigue was dose-limiting with SJG-136 60 microg/m2/day administered on days 1, 8 and 15 of a 28-day cycle. Grade 3 thrombocytopenia and delayed onset liver toxicity were seen in one patient each. PK parameters of SJG-136 indicated dose-proportional increases in systemic exposure with increasing doses. No objective responses were seen. CONCLUSION: For patients with advanced solid tumors, the MTD of SJG-136 is 40 microg/m2/day administered on days 1, 8 and 15 of a 28-day cycle. The major dose limiting toxicity was fatigue. Alternative dosing strategies are now being evaluated.
PURPOSE:SJG-136 is a pyrrolobenzodiazepine dimer that forms DNA crosslinks and has demonstrated broad antitumor activity. We undertook this trial to determine the maximum-tolerated dose (MTD), toxicities and pharmacokinetic (PK) profile of SJG-136 in patients with an advanced solid tumor. PATIENTS AND METHODS: In this phase I study, patients were treated with SJG-136 on days 1, 8 and 15 of a 28-day cycle. Dose levels studied were 10, 20, 40 and 60 microg/m2. PK parameters of SJG-136 were assessed following the intravenous administration of SJG-136 on days 1 and 15 of cycle 1. RESULTS: Twenty-one patients with advanced solid tumors were treated. Patients had a median of two prior chemotherapy regimens. Fatigue was dose-limiting with SJG-136 60 microg/m2/day administered on days 1, 8 and 15 of a 28-day cycle. Grade 3 thrombocytopenia and delayed onset liver toxicity were seen in one patient each. PK parameters of SJG-136 indicated dose-proportional increases in systemic exposure with increasing doses. No objective responses were seen. CONCLUSION: For patients with advanced solid tumors, the MTD of SJG-136 is 40 microg/m2/day administered on days 1, 8 and 15 of a 28-day cycle. The major dose limiting toxicity was fatigue. Alternative dosing strategies are now being evaluated.
Authors: Michael C Alley; Melinda G Hollingshead; Christine M Pacula-Cox; William R Waud; John A Hartley; Philip W Howard; Stephen J Gregson; David E Thurston; Edward A Sausville Journal: Cancer Res Date: 2004-09-15 Impact factor: 12.701
Authors: K D Paull; R H Shoemaker; L Hodes; A Monks; D A Scudiero; L Rubinstein; J Plowman; M R Boyd Journal: J Natl Cancer Inst Date: 1989-07-19 Impact factor: 13.506
Authors: M S Puvvada; S A Forrow; J A Hartley; P Stephenson; I Gibson; T C Jenkins; D E Thurston Journal: Biochemistry Date: 1997-03-04 Impact factor: 3.162
Authors: S J Gregson; P W Howard; J A Hartley; N A Brooks; L J Adams; T C Jenkins; L R Kelland; D E Thurston Journal: J Med Chem Date: 2001-03-01 Impact factor: 7.446
Authors: Daniel Hochhauser; Timothy Meyer; Victoria J Spanswick; Jenny Wu; Peter H Clingen; Paul Loadman; Margaret Cobb; Lindsey Gumbrell; Richard H Begent; John A Hartley; Duncan Jodrell Journal: Clin Cancer Res Date: 2009-03-10 Impact factor: 12.531
Authors: John A Hartley; Victoria J Spanswick; Natalie Brooks; Peter H Clingen; Peter J McHugh; Daniel Hochhauser; R Barbara Pedley; Lloyd R Kelland; Michael C Alley; Robert Schultz; Melinda G Hollingshead; Karen M Schweikart; Joseph E Tomaszewski; Edward A Sausville; Stephen J Gregson; Philip W Howard; David E Thurston Journal: Cancer Res Date: 2004-09-15 Impact factor: 12.701
Authors: Alicia J Angelbello; Jonathan L Chen; Jessica L Childs-Disney; Peiyuan Zhang; Zi-Fu Wang; Matthew D Disney Journal: Chem Rev Date: 2018-01-11 Impact factor: 60.622
Authors: Maciej Kaliszczak; Dyeison Antonow; Katan I Patel; Philip Howard; Duncan I Jodrell; David E Thurston; Sylvie M Guichard Journal: AAPS J Date: 2010-08-12 Impact factor: 4.009
Authors: John A Hartley; Anzu Hamaguchi; Marissa Coffils; Christopher R H Martin; Marie Suggitt; Zhizhi Chen; Stephen J Gregson; Luke A Masterson; Arnaud C Tiberghien; Janet M Hartley; Christopher Pepper; Thet Thet Lin; Christopher Fegan; David E Thurston; Philip W Howard Journal: Cancer Res Date: 2010-07-26 Impact factor: 12.701
Authors: John A Hartley; Anzu Hamaguchi; Marie Suggitt; Stephen J Gregson; David E Thurston; Philip W Howard Journal: Invest New Drugs Date: 2011-03-08 Impact factor: 3.850
Authors: Khondaker M Rahman; Helena Rosado; Joao B Moreira; Eva-Anne Feuerbaum; Keith R Fox; Eva Stecher; Philip W Howard; Stephen J Gregson; Colin H James; Maria de la Fuente; Denise E Waldron; David E Thurston; Peter W Taylor Journal: J Antimicrob Chemother Date: 2012-04-30 Impact factor: 5.790
Authors: Maria Mellinas-Gomez; Victoria J Spanswick; Solange R Paredes-Moscosso; Matthew Robson; R Barbara Pedley; David E Thurston; Stephen J Baines; Anneliese Stell; John A Hartley Journal: BMC Vet Res Date: 2015-08-19 Impact factor: 2.741